Wednesday, May 26, 2010 7:24:10 PM
Totally agree with Piecemaker's assessment. If this is a conference to present research, the abstract would have been submitted AT LEAST 6 months ago, which makes it all but impossible that she will be presenting work related to NNVC.
Also, how is it that everyone is on a fist name basis with Dr. Harris? I have a PhD myself (and I always ask people to call me by my first name) but if I met "Eva" tomorrow I would call her Dr. Harris until she told me otherwise. I understand the nature of the posts and we are all happy to have her on our team, but lets show her some well deserved respect. After all, we call DrFeelgood "Doc" and his PhD is in English
Although he is more knowledgeable about biomedical development than many of the MDs I work with.
Also, how is it that everyone is on a fist name basis with Dr. Harris? I have a PhD myself (and I always ask people to call me by my first name) but if I met "Eva" tomorrow I would call her Dr. Harris until she told me otherwise. I understand the nature of the posts and we are all happy to have her on our team, but lets show her some well deserved respect. After all, we call DrFeelgood "Doc" and his PhD is in English
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
